Evaluation of Mannheim Peritonitis Index and APACHE II Score in Predicting Mortality and Morbidity in Patients with Peritonitis from Hollow Viscus Perforation

Dr. Shivangi Rakesh Singh, Dr. R. G. Naniwadekar
Resident, Department of General Surgery, Krishna Institute Of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed To Be University), Karad, Maharashtra, India.
Corresponding Author: Dr. Shivangi Rakesh Singh

Cite this paper as: Shivangi Rakesh Singh, R. G. Naniwadekar (2024) Evaluation of Mannheim Peritonitis Index and APACHE II Score in Predicting Mortality and Morbidity in Patients with Peritonitis from Hollow Viscus Perforation. *Frontiers in Health Informatics, 13* (3) 6225-6238

Abstract
Peritonitis caused by hollow viscus perforation (HVP) is a life-threatening condition that requires prompt assessment and intervention. Accurate risk stratification tools are crucial in managing these cases effectively, guiding clinical decisions, and allocating resources. This study evaluates the predictive accuracy of two scoring systems, the Mannheim Peritonitis Index (MPI) and the Acute Physiology and Chronic Health Evaluation (APACHE II), in assessing mortality and morbidity in patients with HVP-induced peritonitis. A retrospective cohort analysis of 300 patients was conducted, categorizing them into low, moderate, and high-risk groups based on MPI and APACHE II scores at admission. The primary outcomes were mortality within 30 days and morbidity markers, including ICU admission and length of hospital stay. Results demonstrated that both MPI and APACHE II scores were effective in predicting outcomes, with high-risk patients showing significantly higher mortality and morbidity rates. Receiver Operating Characteristic (ROC) curve analysis yielded an AUC of 0.84 for MPI and 0.87 for APACHE II, indicating slightly higher predictive accuracy for APACHE II. However, the difference was not statistically significant. This study suggests that both scoring systems are valuable for clinical use in peritonitis cases, with MPI offering a targeted approach and APACHE II providing a broader assessment of patient status.

Keywords: *Peritonitis, Hollow Viscus Perforation, Mannheim Peritonitis Index (MPI), APACHE II, Mortality Prediction, Morbidity, Risk Stratification*

Introduction

Peritonitis, a severe inflammatory condition of the peritoneum, is often life-threatening and demands prompt and accurate diagnosis for effective management. The peritoneum is a serous membrane lining the abdominal cavity and covering the visceral organs. When exposed to bacterial or chemical irritants, such as those resulting from hollow viscus perforations (HVPs), this tissue becomes inflamed, causing a range of severe symptoms. Peritonitis is commonly classified into primary, secondary, and tertiary categories based on etiology. Primary peritonitis, also known as spontaneous bacterial peritonitis, typically occurs without an identifiable source of infection and is often associated with conditions like liver cirrhosis and ascites [1]. Secondary peritonitis, the most frequent type, results from breaches in the gastrointestinal tract, commonly due to conditions like appendicitis, diverticulitis, or HVPs. Tertiary peritonitis, on the other hand, is often a recurrent infection occurring post-treatment of primary or secondary cases and is typically seen in immunocompromised patients or those in critical condition.

Hollow viscus perforation is a significant cause of secondary peritonitis, where the rupture of a part of the gastrointestinal (GI) tract, such as the stomach or intestines, allows gut contents to spill into the sterile peritoneal cavity. This can lead to a severe inflammatory response and rapid progression to systemic inflammation and sepsis. Common causes of HVP include trauma, ulcers, diverticulitis, and bowel obstructions. These cases are often accompanied by the leakage of bacteria-laden contents from the GI tract, which heightens the risk of infection and can escalate rapidly if left untreated. Clinically, peritonitis presents with severe abdominal pain, fever, nausea, vomiting, and other systemic signs, which typically prompt immediate medical attention. Laboratory tests, including white blood cell counts and C-reactive protein (CRP) levels, are helpful in identifying infection, while imaging techniques such as X-rays, ultrasound, and computed tomography (CT) scans are instrumental in identifying the extent and source of infection.

Timely and accurate prediction of outcomes in peritonitis cases, particularly those resulting from HVP, is critical for optimal treatment and resource allocation. Mortality rates in peritonitis cases are high, especially in the presence of complications or delayed intervention. Early prediction of outcomes can guide treatment strategies, enabling clinicians to categorize patients based on the severity of their condition, prioritize those at higher risk for intensive interventions, and provide supportive care to improve prognosis [2]. The use of scoring systems has proven essential in peritonitis management, providing a standardized means of assessing severity and predicting mortality and morbidity risks. Two widely recognized scoring systems, the Mannheim Peritonitis Index (MPI) and the Acute Physiology and Chronic Health Evaluation (APACHE) II score, are frequently utilized for this purpose. These tools aid in decision-making concerning the intensity of monitoring, surgical intervention, and level of care required, such as intensive care unit (ICU) admission.

The **Mannheim Peritonitis Index (MPI)** is a specific scoring system developed for peritonitis cases, incorporating clinical and laboratory parameters to provide a cumulative score that correlates with the risk of mortality. Introduced by Wacha and Linder in 1983, MPI is one of the first scoring systems developed to address peritonitis exclusively. The system includes factors like age, sex, the presence of shock, origin and extent of peritonitis, and organ failure. Each parameter is assigned a score based on its prognostic value, with higher scores indicating a greater likelihood of mortality. For example, the MPI assigns points for risk factors such as age over 50, presence of malignancy, preoperative duration of symptoms over 24 hours, and the extent of contamination in the abdominal cavity [3]. These factors are known to correlate with worse outcomes, and MPI provides a clear and actionable metric that clinicians can use at the point of diagnosis. The scoring system categorizes patients into low, moderate, and high-risk groups, enabling medical professionals to stratify patients and prioritize interventions for those with higher risk scores. Studies have shown that the MPI score has a high degree of accuracy in predicting mortality among patients with peritonitis, making it a valuable tool for assessing patient severity and guiding treatment plans.

The **Acute Physiology and Chronic Health Evaluation (APACHE) II score**, developed in 1985 by Knaus et al., is a more general severity-of-disease classification system. Initially designed for use in ICU patients, the APACHE II score has since been adapted for a wide range of medical conditions, including peritonitis. The scoring system evaluates a set of physiological parameters, including vital signs, laboratory values, and previous health status, within the first 24 hours of admission. The APACHE II score also includes age and chronic health evaluation points, accounting for the patient's baseline health status, to provide a composite score that predicts the risk of mortality [4]. Parameters such as mean arterial pressure, respiratory rate, serum potassium, and

Glasgow Coma Scale (GCS) score are integrated into the APACHE II model, each contributing to a total score. This approach enables clinicians to objectively assess physiological severity in critically ill patients, making it particularly valuable in ICU settings where rapid and precise risk assessment is crucial.

Although the APACHE II score was not originally developed specifically for peritonitis, its broad applicability and ability to assess physiological stress make it a practical choice for peritonitis cases as well. The score allows for the stratification of patients based on overall illness severity, which has implications for treatment plans and resource allocation. Higher APACHE II scores indicate a greater likelihood of mortality, enabling clinicians to tailor their interventions accordingly. Unlike the MPI, which is exclusively focused on factors associated with peritonitis, the APACHE II score provides a broader assessment of patient health, which can be advantageous in cases where comorbidities and systemic physiological status play a critical role in prognosis.

Both MPI and APACHE II scores offer unique advantages in peritonitis management. The MPI's specificity to peritonitis factors, such as peritoneal contamination and disease duration, allows for a focused approach in evaluating the severity of peritonitis. Conversely, APACHE II's inclusivity of general physiological parameters provides a more comprehensive assessment that accounts for the patient's overall critical status. However, both scoring systems have limitations. MPI may overlook the impact of comorbidities that are not directly related to peritonitis, while APACHE II may lack the specificity required to assess the intricacies of peritonitis cases, potentially leading to an overgeneralized risk assessment.

In summary, MPI and APACHE II scores serve as valuable prognostic tools in the management of peritonitis due to hollow viscus perforation. The MPI offers peritonitis-specific assessments that assist in surgical and clinical decision-making, while the APACHE II score provides a general overview of patient status that can inform treatment across a range of critical conditions. When used together, these tools enable a nuanced assessment that can guide therapeutic interventions and improve patient outcomes, ultimately contributing to more efficient and targeted use of healthcare resources in high-risk peritonitis cases.

I. Aim and Objectives

Aim: The aim of this study is to evaluate the effectiveness of the Mannheim Peritonitis Index (MPI) and the Acute Physiology and Chronic Health Evaluation (APACHE II) score in predicting outcomes in patients with peritonitis due to hollow viscus perforation. By assessing the predictive capabilities of each scoring system, this study seeks to determine which tool provides the most accurate assessment for guiding clinical decision-making and improving patient prognosis.

Objectives:

1. **To stratify patients with peritonitis based on MPI and APACHE II scores at admission:** This objective involves using MPI and APACHE II scores to categorize patients into risk groups at the time of admission. This stratification will facilitate a preliminary understanding of the severity of each case, allowing for immediate prioritization and treatment planning.

2. **To correlate observed mortality rates with scores obtained:**
This objective aims to establish a statistical relationship between the scores from MPI and APACHE II and the actual mortality rates observed in the patient cohort. By comparing predicted mortality with actual outcomes, the study will assess each scoring system's predictive accuracy.

3. **To identify the most effective scoring system for predicting outcomes:**
The final objective is to determine which scoring system—MPI or APACHE II—more accurately predicts mortality and morbidity in peritonitis patients. This will involve a comparative analysis based on sensitivity, specificity, and overall predictive value, enabling clinicians to select the optimal tool for assessing and managing peritonitis cases.

II. Review of Literature

Peritonitis is a severe, potentially life-threatening condition characterized by inflammation of the peritoneum, a serous membrane lining the abdominal cavity and covering the internal organs. This inflammation is generally the result of infection, often following a breach in the gastrointestinal (GI) tract, or by a non-infectious irritant. Peritonitis is commonly classified into three types based on its origin: primary, secondary, and tertiary peritonitis. Primary peritonitis, also known as spontaneous bacterial peritonitis (SBP), typically occurs in patients with chronic liver disease and ascites, where bacteria enter the peritoneal cavity without a clear source of infection. Tertiary peritonitis is a recurrent or persistent infection that may arise after treatment of primary or secondary peritonitis, often affecting critically ill or immunocompromised patients [5].

Secondary peritonitis is the most common type and typically results from a breach in the GI tract, a situation referred to as hollow viscus perforation (HVP). In HVP, perforation of a hollow organ such as the stomach, intestines, or colon allows the contents of the GI tract to spill into the sterile peritoneal cavity. This spillage often contains bacteria, digestive enzymes, and other irritants, leading to rapid inflammation, infection, and, if left untreated, sepsis. Hollow viscus perforations can arise from a variety of causes, including peptic ulcers, diverticulitis, trauma, malignancies, or complications from procedures like endoscopy [6]. When perforation occurs, the immediate exposure of the peritoneum to gastric or intestinal contents triggers a cascade of immune responses, including the recruitment of inflammatory cells and release of cytokines, which can lead to systemic inflammatory response syndrome (SIRS), sepsis, or septic shock.

Patients with HVP-induced peritonitis typically present with severe abdominal pain, guarding, fever, nausea, and signs of peritoneal irritation, such as rebound tenderness and abdominal rigidity. Diagnostic approaches involve a combination of clinical examination, laboratory tests, and imaging studies. Laboratory findings such as elevated white blood cell counts, C-reactive protein (CRP), and other markers of inflammation often signal infection. Imaging techniques, including X-rays, ultrasound, and computed tomography (CT) scans, are commonly used to confirm perforation and assess the severity of peritoneal contamination [7]. Timely intervention is crucial due to the rapid progression of the condition, and typical management includes surgical repair of the perforation, broad-spectrum antibiotics, and supportive care. Despite advances in surgical techniques and antibiotic therapy, mortality rates for peritonitis caused by HVP remain high, especially in cases with delayed treatment.

The severity and rapid progression of peritonitis, particularly in HVP cases, underscore the need for reliable tools to assess and predict patient outcomes. Prognostic scoring systems are invaluable for stratifying patients based on severity, enabling more targeted interventions, optimizing resource allocation, and aiding in clinical decision-making [8]. Two widely recognized scoring systems—the Mannheim Peritonitis Index (MPI) and the Acute Physiology and Chronic Health Evaluation (APACHE II) score—have been developed and extensively validated to meet these needs.

The Mannheim Peritonitis Index (MPI) was developed in the 1980s by Wacha and Linder at the University of Mannheim, Germany, specifically for peritonitis cases. MPI was one of the first scoring systems tailored to peritonitis and remains one of the most widely used tools in this field. The MPI scoring system is based on a series of prognostic factors that are known to correlate with patient outcomes in peritonitis [9]. These factors include age, gender, the origin of peritonitis, the extent of contamination, and the presence of organ dysfunction or comorbidities. Each parameter is assigned a score, and the cumulative score helps classify patients into low, moderate, and high-risk groups for mortality. For instance, higher points are assigned to older age, male gender, extended contamination, or the presence of malignancy, with higher scores indicating worse outcomes.

The MPI's simplicity, high sensitivity, and specificity make it a valuable tool for clinicians. It allows for quick, bedside assessment without requiring complex laboratory data, which is particularly useful in emergency and resource-limited settings. Numerous studies have validated MPI as an effective predictor of mortality and morbidity in peritonitis cases, demonstrating that patients with high MPI scores have higher rates of mortality and complications. However, while MPI is specific to peritonitis and highly useful in this context, it does have limitations, such as the exclusion of certain physiological parameters that may impact outcomes in critically ill patients [10].

The Acute Physiology and Chronic Health Evaluation (APACHE) II score was introduced in 1985 by Knaus et al. as a general severity-of-disease classification system for critically ill patients in the intensive care unit (ICU). Unlike MPI, which is specific to peritonitis, the APACHE II score is designed for a broad range of critical conditions, making it one of the most widely used and validated scoring systems in ICU settings. The APACHE II score is based on a set of 12 physiological parameters, including body temperature, mean arterial pressure, heart rate, respiratory rate, arterial blood pH, serum sodium, potassium, creatinine levels, hematocrit, and the Glasgow Coma Scale (GCS) score. It also accounts for age and chronic health status by incorporating chronic health points based on the presence of comorbidities, such as chronic renal failure or liver cirrhosis. Each variable is assigned a score based on the level of deviation from normal values, and the cumulative APACHE II score correlates with the risk of mortality.

APACHE II's ability to assess physiological stress across diverse conditions makes it valuable for peritonitis cases, where patient outcomes are often influenced by underlying physiological status. Studies have shown that APACHE II is effective in predicting mortality in peritonitis patients and can be especially useful in cases where other comorbidities play a critical role. The APACHE II score's sensitivity and specificity have been validated across various patient populations and clinical settings, confirming its reliability as a prognostic tool. However, because it is not specific to peritonitis, APACHE II may not capture certain key factors of peritonitis cases, such as the extent of contamination or type of infection, which are accounted for in MPI.

Both MPI and APACHE II scoring systems offer unique advantages in managing peritonitis cases. MPI's specificity to peritonitis factors, such as contamination level and preoperative duration of symptoms, provides a targeted approach for assessing severity in peritonitis patients. APACHE II, on the other hand, provides a comprehensive assessment of the patient's general physiological status, which is valuable in critically ill patients with complex clinical profiles. Comparative studies have shown that while both scoring systems are effective for predicting outcomes, each has its strengths: MPI's specificity makes it more sensitive for peritonitis, while APACHE II's inclusion of broader physiological factors enables it to assess the overall health of critically ill patients, including those with comorbidities.

In conclusion, the historical development of MPI and APACHE II reflects an ongoing commitment in medical research to improve outcome prediction for peritonitis and other critical conditions. These scoring systems play a critical role in peritonitis management, aiding clinicians in making informed decisions, stratifying patients based on risk, and optimizing the allocation of healthcare resources. When used in combination, MPI and APACHE II provide a comprehensive assessment framework that can help improve patient outcomes in high-risk peritonitis cases.

III. Materials and Methods

a. Study Design, Population, and Inclusion/Exclusion Criteria

This study was designed as a retrospective cohort analysis to evaluate the predictive accuracy of the Mannheim Peritonitis Index (MPI) and the Acute Physiology and Chronic Health Evaluation (APACHE II) score in patients diagnosed with peritonitis due to hollow viscus perforation (HVP). The goal of this study was to compare the ability of these scoring systems to predict mortality and morbidity outcomes, allowing for an evidence-based approach to selecting the most effective scoring tool for this patient population.

The study population consisted of patients admitted with a clinical diagnosis of peritonitis secondary to hollow viscus perforation. Patients were recruited from the surgical departments of multiple tertiary care centers to ensure a diverse sample that would capture a wide range of demographic and clinical presentations. The study period spanned five years, from January 2019 to December 2023, to allow for a sufficient number of cases and ensure statistical robustness.

Inclusion criteria were:

1. Patients over the age of 18 diagnosed with peritonitis secondary to hollow viscus perforation.
2. Patients who underwent surgical intervention for peritonitis.
3. Patients with complete medical records, including demographic information, laboratory results, and imaging studies.
4. Patients for whom MPI and APACHE II scores could be calculated based on available clinical data at the time of admission.

Exclusion criteria were:

1. Patients under 18 years of age.

2. Patients with peritonitis not caused by hollow viscus perforation (e.g., primary peritonitis or peritonitis due to other infections).
3. Patients with incomplete medical records, including missing data points required for MPI or APACHE II score calculation.
4. Patients who declined surgical intervention or were managed conservatively without surgery.

After applying these criteria, the final sample included 300 patients, providing a statistically significant cohort for analysis of the scoring systems' predictive accuracy. This sample size was determined based on power analysis, ensuring adequate statistical power to detect differences between the MPI and APACHE II scores in predicting mortality and morbidity outcomes.

b. Methodology for Score Calculation and Outcome Assessment

Both MPI and APACHE II scores were calculated for each patient at the time of admission, based on clinical and laboratory data collected during initial assessment. The MPI score was specifically chosen for its peritonitis-focused criteria, while APACHE II was included due to its broader utility in assessing physiological stress in critically ill patients. The score calculation methods are outlined as follows:

1. Mannheim Peritonitis Index (MPI):

The MPI score is calculated based on 10 clinical and demographic variables, each assigned a point value based on its prognostic significance. The factors included are:

- Age: ≥50 years (5 points)
- Gender: Male (1 point)
- Origin of peritonitis (presence of malignancy or other high-risk source) (4 points)
- Preoperative duration of peritonitis symptoms (more than 24 hours) (4 points)
- Extent of contamination (generalized or limited) (6 points)
- Presence of organ dysfunction (7 points)
- Patient's immune status (e.g., immunocompromised or not) (3 points)
- Additional factors, including the presence of malignancy or shock status

A cumulative MPI score is obtained by summing the points assigned to each of the above variables. Patients are then categorized into risk groups based on their total MPI score: low (0–21), moderate (22–29), and high (≥30) risk. This stratification is used to predict mortality, with higher scores indicating greater severity and higher mortality risk.

2. Acute Physiology and Chronic Health Evaluation (APACHE II): APACHE II scoring involves a more comprehensive evaluation of the patient's physiological state, including:
   - Vital signs (temperature, mean arterial pressure, respiratory rate)
   - Arterial blood gas values (pH, partial pressure of oxygen)
   - Serum electrolyte and biochemical parameters (e.g., sodium, potassium, creatinine)
   - Hematologic parameters (e.g., hematocrit, white blood cell count)

- Glasgow Coma Scale (GCS) score for neurological assessment
- Age and chronic health conditions (e.g., presence of chronic renal failure or liver cirrhosis)

Each variable is scored based on the degree of deviation from normal values, with higher points indicating greater abnormality. APACHE II scores are then summed to produce a total score, which correlates with an estimated risk of mortality. Patients are classified into risk categories (low, moderate, and high) based on their APACHE II scores, with higher scores indicating more severe illness and a higher predicted mortality risk.

c. Outcome Assessment:
The primary outcome for this study was patient mortality within 30 days post-admission, chosen as it represents the critical period during which most complications and deaths from peritonitis are likely to occur. Secondary outcomes included morbidity markers such as duration of hospital stay, postoperative complications, need for ICU admission, and duration of mechanical ventilation for those requiring respiratory support. Mortality and morbidity data were obtained from hospital records, verified by reviewing discharge summaries and follow-up notes, ensuring the accuracy and consistency of the outcome data.

d. Data Collection and Statistical Analysis Approach

Data Collection:

Data for each patient were extracted from medical records, including demographic data (age, gender), clinical parameters (vital signs, laboratory results), surgical details, and outcomes. Trained research assistants entered this information into a secure, de-identified database to maintain patient confidentiality. Each patient record was reviewed by two independent researchers to ensure data accuracy, with discrepancies resolved by consensus or by consulting the original medical record.

Statistical Analysis:

The statistical analysis aimed to evaluate the predictive power of the MPI and APACHE II scoring systems for mortality and morbidity in peritonitis patients. All statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) software, version 26.0. The specific analysis methods used were as follows:

1. Descriptive Statistics:

Basic demographic data were summarized using descriptive statistics, with means and standard deviations calculated for continuous variables (e.g., age, hospital stay duration) and frequencies and percentages for categorical variables (e.g., gender, comorbidity presence).

2. Comparative Analysis of Scoring Systems:

The predictive accuracy of MPI and APACHE II was assessed by comparing the distribution of mortality and morbidity outcomes across different risk categories in each scoring system. Chi-square tests were used to assess associations between categorical variables, while t-tests and analysis of variance (ANOVA) were used for comparisons involving continuous variables.

3. Receiver Operating Characteristic (ROC) Curve Analysis:

To evaluate the sensitivity and specificity of MPI and APACHE II scores in predicting mortality, ROC curve analysis was performed. The area under the curve (AUC) was calculated for each scoring system, with values closer to 1 indicating better predictive accuracy. Cutoff values for high-risk stratification were selected based on ROC analysis to optimize sensitivity and specificity for each scoring tool.

4. Logistic Regression Analysis:

To assess the independent predictive value of MPI and APACHE II scores for mortality, a multivariate logistic regression model was constructed. Variables included in the model were MPI and APACHE II scores, age, gender, comorbidity status, and duration of symptoms before surgical intervention. Adjusted odds ratios (OR) with 95% confidence intervals (CI) were calculated to determine the relative risk associated with higher scores in each system.

5. Kaplan-Meier Survival Analysis:

Kaplan-Meier survival analysis was conducted to compare survival probabilities between patient groups stratified by MPI and APACHE II scores. The log-rank test was used to assess differences in survival curves, providing a visual representation of survival trends across risk groups in each scoring system.

6. P-value and Statistical Significance:

For all analyses, a p-value < 0.05 was considered statistically significant. Where appropriate, Bonferroni correction was applied to account for multiple comparisons and reduce the risk of type I errors.

e. Ethical Considerations:

The study protocol was reviewed and approved by the Institutional Review Boards (IRBs) of the participating centers. Informed consent was waived due to the retrospective nature of the study, as patient data were de-identified and handled confidentially according to ethical guidelines.

IV. Observation and Results

1. Demographic Distribution and Scoring Analysis

The study sample included a total of 300 patients diagnosed with peritonitis due to hollow viscus perforation. The demographic distribution and average scores for MPI and APACHE II are summarized in Table 1.

Table 1: Demographic Distribution and Scoring Summary	
Variable	**N (%)** or **Mean ± SD**
Total Patients	300

Age (years)	52.4 ± 15.2
Gender	
Male	180 (60%)
Female	120 (40%)
Comorbidities	
Present	145 (48.3%)
Absent	155 (51.7%)
MPI Score	24.6 ± 8.5
APACHE II Score	18.2 ± 7.4

Explanation: The study sample included 60% male and 40% female patients, with a mean age of 52.4 years. Comorbidities were present in approximately 48.3% of patients. The average MPI score was 24.6, and the average APACHE II score was 18.2. This distribution indicates a high-risk population often associated with severe peritonitis cases due to HVP.

2.Mortality and Morbidity Rates by Score Categories

Patients were categorized into low, moderate, and high-risk groups based on their MPI and APACHE II scores.



Figure 2 . Mortality Rates by MPI and APACHE II Score Categories

 Low Risk: Patients in the low-risk category had a mortality rate of 4% with MPI and 6% with APACHE II, while morbidity rates were 6% and 8%, respectively.

 Moderate Risk: Moderate-risk patients had mortality rates of 15% with MPI and 18% with APACHE II, with morbidity rates of 20% and 25%.

 High Risk: High-risk patients showed the highest mortality and morbidity, with MPI at 50% mortality and APACHE II at 55%, and morbidity rates of 66% and 70%, respectively.

3. Comparative Analysis of MPI and APACHE II Effectiveness

To evaluate the effectiveness of MPI and APACHE II in predicting mortality, we conducted a Receiver Operating Characteristic (ROC) curve analysis, calculating the Area Under the Curve (AUC) for each scoring system. The AUC values and associated figures are shown in Table 4 and Figure 2.

Table 4: ROC Analysis for MPI and APACHE II	
Scoring System	AUC (95% CI)
MPI	0.84 (0.78-0.89)
APACHE II	0.87 (0.82-0.92)

Explanation: The ROC analysis revealed that both MPI and APACHE II had high predictive accuracy for mortality, with AUC values of 0.84 and 0.87, respectively. Although APACHE II had a slightly higher AUC, indicating a marginally better predictive capability, the difference was not statistically significant ($p > 0.05$). This suggests that both scoring systems are reliable tools for predicting mortality in peritonitis patients due to HVP.



Figure 3 . ROC Curves for MPI and APACHE II in Predicting Mortality

V. Discussion

The findings of this study provide valuable insights into the utility of the Mannheim Peritonitis Index (MPI) and the Acute Physiology and Chronic Health Evaluation (APACHE II) score as predictive tools for mortality and morbidity in patients with peritonitis due to hollow viscus perforation (HVP). Both scoring systems demonstrated a strong correlation with patient outcomes, underscoring their relevance in clinical settings for stratifying patients based on risk levels and aiding decision-making. This discussion explores the implications of these findings, the comparative strengths and limitations of each scoring system, and their potential roles in clinical practice.

A. Predictive Value of MPI and APACHE II Scores

Our results indicate that both MPI and APACHE II scores effectively stratify patients by risk, with significant differences in mortality and morbidity observed across low, moderate, and high-risk groups. High-risk patients, as defined by each scoring system, exhibited markedly higher mortality rates (50% for MPI and 55% for APACHE II), reflecting the accuracy of these tools in identifying critically ill patients who are most likely to benefit from intensive care and early intervention. This stratification aligns with previous research that emphasizes the importance of MPI and APACHE II scores in predicting peritonitis outcomes, reaffirming their use as reliable, evidence-based predictors.

B. Comparison of MPI and APACHE II Scores

While both scores proved to be useful, each has unique strengths. The MPI score, designed specifically for peritonitis, includes peritonitis-related factors like the extent of peritoneal contamination, preoperative duration of symptoms, and immune status, providing a targeted approach to assessing risk in peritonitis cases. This specificity makes MPI a practical choice for surgical settings where quick, bedside risk assessment is crucial. Our study's findings are consistent with other studies showing that MPI has high sensitivity and specificity for mortality prediction in peritonitis, allowing for effective patient stratification with relatively simple criteria.

APACHE II, on the other hand, is a more comprehensive scoring system that considers a broader range of physiological parameters and chronic health conditions. This broader assessment provides valuable insight into the overall health and physiological reserve of patients, which is particularly beneficial in cases with complex comorbidities. APACHE II's slightly higher area under the ROC curve (AUC) of 0.87 compared to MPI's 0.84 in this study suggests that APACHE II may offer a slight advantage in predictive accuracy, especially in cases where patient outcomes are influenced by multiple health conditions. However, the difference in AUC was not statistically significant, indicating that both systems are comparably effective in mortality prediction for peritonitis patients.

C. Clinical Implications

The application of MPI and APACHE II scores in clinical practice can support a more structured approach to peritonitis management, enabling clinicians to prioritize high-risk patients for intensive monitoring and resources. MPI, with its simplicity and focus on peritonitis-specific factors, is especially useful in emergency and surgical settings, where rapid and targeted risk assessment is necessary. APACHE II's broader scope can complement MPI, providing additional information on physiological stress and chronic health, which may guide management decisions, especially for patients requiring comprehensive ICU care.

In clinical settings, using MPI as an initial screening tool may be particularly beneficial for rapid assessment at the point of admission, while APACHE II could be used subsequently in intensive care to provide a detailed assessment of the patient's condition. Combining these tools may enhance overall predictive accuracy, especially in diverse patient populations with varying health profiles.

D. Strengths and Limitations

This study's strengths include its large sample size, comprehensive analysis of both scoring systems, and the focus on a critical patient population with peritonitis from HVP. However, there are limitations to consider. As a retrospective study, it relied on existing medical records, which may introduce biases associated with missing or inconsistent data. Additionally, the study was conducted across multiple tertiary care centers, which, while increasing the generalizability of findings, may introduce variability in clinical practices and data recording methods.

Another limitation is that MPI, while effective, does not account for comorbid conditions unrelated to peritonitis, potentially limiting its predictive accuracy in patients with significant chronic illnesses. APACHE II, though comprehensive, is more complex and requires multiple physiological measurements, making it less feasible as a quick bedside assessment tool.

VI. Conclusion

In cases of peritonitis due to hollow viscus perforation, early and accurate prediction of patient outcomes is essential for guiding clinical decisions and optimizing resource allocation. This study compared the effectiveness of the Mannheim Peritonitis Index (MPI) and the Acute Physiology and Chronic Health Evaluation (APACHE II) score in predicting mortality and morbidity in a high-risk patient population. Both scoring systems proved valuable, with a clear correlation between higher scores and increased rates of mortality and complications. While the APACHE II score showed slightly higher predictive accuracy, as indicated by a marginally greater area under the ROC curve (AUC), the difference between the two scoring systems was not statistically significant. MPI, with its peritonitis-specific criteria, offers a simpler, targeted approach that can be used efficiently at the bedside, while APACHE II provides a more comprehensive evaluation that may be advantageous in complex cases with multiple comorbidities. Overall, both MPI and APACHE II are effective tools for risk stratification in peritonitis cases, enabling clinicians to identify high-risk patients who may benefit from intensive monitoring and early intervention. The complementary use of both scoring systems may further enhance predictive accuracy, especially in diverse patient populations. Future research should explore the integration of these tools into decision-making protocols and evaluate their applicability in varied clinical settings.

References

[1] Wacha, H., & Linder, M. M. (1983). The Mannheim Peritonitis Index: Prediction of risk of death from peritonitis. Theoretical Surgery, 1(3), 169-173.
[2] Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1985). APACHE II: A severity of disease classification system. Critical Care Medicine, 13(10), 818-829.
[3] Sartelli, M., Catena, F., Ansaloni, L., Coccolini, F., Corbella, D., Moore, E. E., & Biffl, W. L. (2014). Complicated intra-abdominal infections in Europe: A comprehensive review of the CIAO study. World Journal of Emergency Surgery, 9(1), 1-8.

[4] Kumar, S., Tiwari, R., & Anupama, B. (2016). Predicting mortality in peritonitis: Evaluation of Mannheim Peritonitis Index, Apache II, and SOFA scoring systems. Indian Journal of Surgery, 78(6), 515-521.
[5] Marshall, J. C., Maier, R. V., Jimenez, M., & Dellinger, E. P. (2004). Source control in the management of severe sepsis and septic shock: An evidence-based review. Critical Care Medicine, 32(11), S513-S526.
[6] Schein, M., Assalia, A., & Bachus, H. (1995). Minimal antibiotic therapy after emergency abdominal surgery: A prospective study. British Journal of Surgery, 82(4), 608-611.
[7] Bruns, B., Mauldin, P., Lam, C., Sigakis, M., & Kazi, G. (2017). Validation of the Mannheim Peritonitis Index for predicting outcomes in patients with secondary peritonitis. American Journal of Surgery, 214(4), 584-589.
[8] Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., & Thijs, L. G. (1996). The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Medicine, 22(7), 707-710.
[9] Cheatham, M. L., Chapman, W. C., Key, S. P., & Sawyers, J. L. (1995). Predicting death in patients with intra-abdominal sepsis: Implications for management. Archives of Surgery, 130(6), 633-639.
[10] Belohlavek, J., Rohn, V., & Mirka, H. (2002). Prognostic factors in secondary peritonitis. Journal of Clinical Gastroenterology, 35(1), 17-21.